Osteoporosis Drugs, Dementia Shock

Yvonne Li assisting a customer at a pharmacy counter — Photo: Gorodenkoff / Shutterstock

A pill millions of older Americans already take for brittle bones may be doing something extra: protecting the brain.

Story Snapshot

A Hong Kong study of over 121,000 adults found bisphosphonate users had lower rates of Alzheimer’s and related dementia.
The drugs showed a 24% lower dementia risk compared to other osteoporosis medicines, and a 16% lower risk compared to no treatment at all.
The medicines studied included alendronate, ibandronate, risedronate, and zoledronate, all widely prescribed for bone loss.
The study’s own author says this is not proof the drugs prevent dementia, and a clinical trial is needed to confirm it.

A Massive Hong Kong Study Finds A Surprising Brain Benefit

Researchers tracked 121,492 adults age 60 and older who had osteoporosis or a fragility fracture, using health records from 2005 through 2020, with follow-up into 2021. The study, published in Alzheimer’s & Dementia, compared people on nitrogen-containing bisphosphonates against two other groups: people on different osteoporosis drugs, and people on no bone medicine at all.

The numbers were striking. Compared to patients taking other osteoporosis drugs, bisphosphonate users had a 24% lower risk of developing Alzheimer’s disease or a related dementia. Compared to patients on no treatment at all, the risk was 16% lower. Both results point the same direction, even if the size of the benefit shifts depending on who you compare against.

The drugs in question are not exotic. Alendronate, ibandronate, risedronate, and zoledronate sit in medicine cabinets across the country, prescribed routinely after a hip fracture or a worrying bone scan. If a connection to dementia prevention holds up, it would touch an enormous number of older patients already taking these pills for an entirely different reason.

Why Scientists Are Calling This A Signal, Not A Cure

Study author Ching-Lung Cheung was blunt about the limits of the finding. “Our findings therefore do not prove that bisphosphonate use reduces dementia risk; this needs confirmation in a clinical trial,” he said. That is not scientific hedging for its own sake. It reflects a real gap between watching patterns in medical records and proving a drug changes outcomes.

The study compared patients who were already prescribed these drugs by their doctors, not patients randomly assigned in a controlled trial. That matters because healthier, more health-conscious patients may be more likely to get prescribed and stick with bone medication in the first place, a pattern researchers call healthier-user bias. Sorting that out requires a randomized trial, not another records review.

The Bone-Brain Connection Researchers Are Chasing

Scientists have floated a “bone-brain axis” as a possible explanation, the idea that chemical signals from bone remodeling could influence inflammation or vascular health in ways that affect the brain. It is a promising hypothesis, but the current study measured dementia diagnoses in medical records. It did not test blood markers, brain scans, or any direct biological pathway connecting the drug to brain tissue.

That gap between association and mechanism is exactly where responsible science should pump the brakes before headlines run ahead of the data. A result this size, in a population this large, deserves serious follow-up. It does not yet deserve a prescription-pad recommendation for dementia prevention, and no researcher involved is claiming otherwise.

What happens next matters more than the headline number. Researchers are calling for a randomized trial that tracks dose, duration, and cognitive testing over time, along with replication studies outside Hong Kong to see if the pattern holds across different populations and prescribing habits. Until then, patients already on these drugs for their bones have a reasonable, evidence-backed reason for hope, not a guarantee, about what it might mean for their minds.